Last reviewed · How we verify
LY2886721 in a Capsule
At a glance
| Generic name | LY2886721 in a Capsule |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Safety Study of LY2886721 Single Doses in Healthy Subjects (PHASE1)
- A Study of Two Dosage Forms of LY2886721 in Healthy Participants (PHASE1)
- A Safety Study of LY2886721 Multiple Doses in Healthy Subjects (PHASE1)
- A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY2886721 in a Capsule CI brief — competitive landscape report
- LY2886721 in a Capsule updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI